HHS pauses enforcement on six peptides at 503A pharmacies
Also in this issue: Hims says it will wait for a final rule
Forwarded this? Get it weekday mornings.
Take. Clinics with a solid 503A partner get a head start on Hims & Hers, the biggest brand in telehealth. CEO Andrew Dudum has said the company will wait for "full and final rulemaking" before selling peptides still under review, Reuters reported in August. That leaves smaller clinics a window to build a BPC-157 or TB-500 menu before Hims starts bidding on the same search terms. Expect 503A pharmacies to undercut research-use-only sellers on price once their first price lists come out. We'd pick a pharmacy that can show its sourcing paperwork early, since HHS calls this a draft it can pull back.
HHS filed a notice Wednesday saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The Federal Register notice says the draft policy "is not binding on HHS or the public." It lasts while FDA builds the 503A bulks list through rulemaking. HHS says it may revisit the policy if a safety signal or quality problem turns up.
HHS lists the conditions in its policy text. Pharmacies need an FDA-registered source with a certificate of analysis. Each product must be single-ingredient and tied to a patient-specific prescription. Each label must read "This is a compounded drug product. Not for resale." Adverse events go to FDA's MedWatch and state regulators. The policy says it aims to "discourage" research-use-only peptides "supplied by foreign manufacturers." 503B outsourcing facilities aren't covered. Ipamorelin, CJC-1295 and GHK-Cu aren't on the list.
NBC News reported that pharmacies "can start offering them now." The notice itself publishes Friday, Oct. 30, with comments open for two weeks. NBC also noted that FDA's own scientists found too little data to show the six are safe and effective. Shabbir Safdar of the Partnership for Safe Medicines told NBC the policy would expose Americans to "untested dangerous substances." Hims shares rose about 6% Wednesday, Yahoo Finance reported.
| When | Who | Side | Status |
|---|---|---|---|
| Tue., Oct. 27 | OIRA, the White House regulatory office | Review | Concluded with changes |
| Fri., Oct. 30 | HHS | Notice publishes | Scheduled |
| Mon., Nov. 9 | Hims & Hers | Q3 results | Watch for peptide timing |
| About Fri., Nov. 13 | Public | Comments on docket HHS-OASH-2026-0496 | Close two weeks after publication |
Enforcement Watch
Ohio suspends 60 medspas after 1,116 inspections
Ohio's pharmacy board inspected 966 medspas and wellness clinics 1,116 times from March 2025 to September 2026, according to a NASCSA deck presented Tuesday. NASCSA is the national group of state controlled-substance regulators. The board issued 60 summary suspensions and 513 written warnings that required corrective action plans. It sent 54 cease-and-desist orders to out-of-state sellers, with referrals to FDA, DEA and other state boards. The deck says 458 clinics "were inspected with no deficiencies or violations." Its closing slides propose a minimum standard for medspa physician supervision and required adverse-event reporting.
Expect other state boards to copy Ohio's inspection push as peptide menus grow.
The Signal
503A/503B
FDA found microbes in a hood before a tirzepatide lot went out
FDA posted the Form 483 from its August inspection of Houston Rx, a Texas sterile compounder. Observation 5 says the firm recovered microbes in its ISO 5 hood after filling a tirzepatide and niacinamide lot. It did not investigate. The lot was released and partly distributed before its recall. Inspectors logged 14 observations in all, including cleanroom pressure reversals and exposed skin during work on a semaglutide lot. A 483 lists an investigator's observations. FDA hasn't made final findings. The firm also recalled sermorelin for "lack of process control," per openFDA records.
Telehealth
California orders a Texas pharmacy to cease and desist
The California Board of Pharmacy ordered CasaPharma Rx of Stafford, Texas, to stop last month (order). The board says the pharmacy isn't licensed in California. CasaPharma's own records show at least 262,482 prescriptions sent into the state over about three years.
Coverage
Federal plans move obesity GLP-1s to 50% coinsurance
Under 2027 OPM brochures, MHBP Standard members will pay 50% of the plan allowance for obesity GLP-1s with no deductible. There's no per-prescription cap. Adults must enroll in CVS Weight Management. The Foreign Service Benefit Plan moves the drugs to 50% coinsurance with no in-network deductible. Expect a federal worker on either plan to compare that 50% share with a clinic's cash-pay price in January.
Evidence
Survey finds 1 in 3 GLP-1 users skip usual channels
A USC and RAND preprint estimates about 32 million US adults used a GLP-1 by October 2025. Roughly a third got it outside traditional channels. It isn't peer reviewed.
Wire
- Correction: Wednesday's issue said FDA's peptide plan was still under White House review. That review concluded Tuesday, Oct. 27, with changes, per Reginfo.gov. The January review date we gave no longer applies.
- Corxel Pharmaceuticals plans to go public by merging with Amanat Acquisition, with a $300 million private raise for its oral GLP-1 pill, BioPharma Dive reported.
- FDA added Chinese ingredient makers Chengdu Shengnuo Biopharm and Nanjing Chengong to Import Alert 66-40. Quartz, citing Bloomberg, reported that both supplied GLP-1 ingredients.
- Dates we're watching:
- Lilly reports Q3 Thursday at 10 a.m. ET.
- The peptide notice publishes Friday.
- Hims reports Monday, Nov. 9.
- Comments close about Friday, Nov. 13.
Share and reply
If this was useful, forward it to a colleague. Hit reply to tell us what you'd like to see more of.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.